Pfizer, Starboard
Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as ...
Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...
As a long-term holding, Pfizer should benefit from demographic trends driving increased healthcare spending globally. The ...
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
Big Pharma is sticking to the recent molecular glue investment trend, with Pfizer now the latest major drugmaker to get in on ...
Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...
Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...
The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...
The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Presentations highlight momentum of Pfizer’s portfolio of infectious disease prevention and treatment options NEW YORK, October 08, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present ...
For fiscal 2024, analysts expect PFE to report an EPS of $2.66, up 44.6% from $1.84 in fiscal 2023 . Shares of PFE have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback